These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29996783)

  • 1. Toxicity associated with tuberculosis chemotherapy in the REMoxTB study.
    Tweed CD; Crook AM; Amukoye EI; Dawson R; Diacon AH; Hanekom M; McHugh TD; Mendel CM; Meredith SK; Murphy ME; Murthy SE; Nunn AJ; Phillips PPJ; Singh KP; Spigelman M; Wills GH; Gillespie SH
    BMC Infect Dis; 2018 Jul; 18(1):317. PubMed ID: 29996783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status.
    Tweed CD; Crook AM; Dawson R; Diacon AH; McHugh TD; Mendel CM; Meredith SK; Mohapi L; Murphy ME; Nunn AJ; Phillips PPJ; Singh KP; Spigelman M; Gillespie SH
    BMC Pulm Med; 2019 Aug; 19(1):152. PubMed ID: 31412895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
    Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    Gillespie SH; Crook AM; McHugh TD; Mendel CM; Meredith SK; Murray SR; Pappas F; Phillips PP; Nunn AJ;
    N Engl J Med; 2014 Oct; 371(17):1577-87. PubMed ID: 25196020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    Boeree MJ; Heinrich N; Aarnoutse R; Diacon AH; Dawson R; Rehal S; Kibiki GS; Churchyard G; Sanne I; Ntinginya NE; Minja LT; Hunt RD; Charalambous S; Hanekom M; Semvua HH; Mpagama SG; Manyama C; Mtafya B; Reither K; Wallis RS; Venter A; Narunsky K; Mekota A; Henne S; Colbers A; van Balen GP; Gillespie SH; Phillips PPJ; Hoelscher M;
    Lancet Infect Dis; 2017 Jan; 17(1):39-49. PubMed ID: 28100438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study.
    Tweed CD; Wills GH; Crook AM; Dawson R; Diacon AH; Louw CE; McHugh TD; Mendel C; Meredith S; Mohapi L; Murphy ME; Murray S; Murthy S; Nunn AJ; Phillips PPJ; Singh K; Spigelman M; Gillespie SH
    BMC Med; 2018 Mar; 16(1):46. PubMed ID: 29592805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
    Conde MB; Mello FC; Duarte RS; Cavalcante SC; Rolla V; Dalcolmo M; Loredo C; Durovni B; Armstrong DT; Efron A; Barnes GL; Marzinke MA; Savic RM; Dooley KE; Cohn S; Moulton LH; Chaisson RE; Dorman SE
    PLoS One; 2016; 11(5):e0154778. PubMed ID: 27159505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: study protocol for a prospective, multicenter, randomized, open-label, phase II trial.
    Lee JY; Kim DK; Lee JK; Yoon HI; Jeong I; Heo E; Park YS; Lee JH; Park SS; Lee SM; Lee CH; Lee J; Choi SM; Park JS; Joh JS; Cho YJ; Lee YJ; Kim SJ; Hwang YR; Kim H; Ki J; Choi H; Han J; Ahn H; Hahn S; Yim JJ
    Trials; 2017 Feb; 18(1):68. PubMed ID: 28193240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
    Dorman SE; Nahid P; Kurbatova EV; Phillips PPJ; Bryant K; Dooley KE; Engle M; Goldberg SV; Phan HTT; Hakim J; Johnson JL; Lourens M; Martinson NA; Muzanyi G; Narunsky K; Nerette S; Nguyen NV; Pham TH; Pierre S; Purfield AE; Samaneka W; Savic RM; Sanne I; Scott NA; Shenje J; Sizemore E; Vernon A; Waja Z; Weiner M; Swindells S; Chaisson RE; ;
    N Engl J Med; 2021 May; 384(18):1705-1718. PubMed ID: 33951360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
    Pettit AC; Phillips PPJ; Kurbatova E; Vernon A; Nahid P; Dawson R; Dooley KE; Sanne I; Waja Z; Mohapi L; Podany AT; Samaneka W; Savic RM; Johnson JL; Muzanyi G; Lalloo UG; Bryant K; Sizemore E; Scott N; Dorman SE; Chaisson RE; Swindells S;
    Clin Infect Dis; 2023 Feb; 76(3):e580-e589. PubMed ID: 36041016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse Model.
    Liu Y; Pertinez H; Davies GR; Gillespie SH; Coates AR; Hu Y
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients.
    Jawahar MS; Banurekha VV; Paramasivan CN; Rahman F; Ramachandran R; Venkatesan P; Balasubramanian R; Selvakumar N; Ponnuraja C; Iliayas AS; Gangadevi NP; Raman B; Baskaran D; Kumar SR; Kumar MM; Mohan V; Ganapathy S; Kumar V; Shanmugam G; Charles N; Sakthivel MR; Jagannath K; Chandrasekar C; Parthasarathy RT; Narayanan PR
    PLoS One; 2013; 8(7):e67030. PubMed ID: 23843980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB study.
    Murphy ME; Wills GH; Murthy S; Louw C; Bateson ALC; Hunt RD; McHugh TD; Nunn AJ; Meredith SK; Mendel CM; Spigelman M; Crook AM; Gillespie SH;
    BMC Med; 2018 Oct; 16(1):189. PubMed ID: 30326959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M
    Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis.
    Burman WJ; Goldberg S; Johnson JL; Muzanye G; Engle M; Mosher AW; Choudhri S; Daley CL; Munsiff SS; Zhao Z; Vernon A; Chaisson RE
    Am J Respir Crit Care Med; 2006 Aug; 174(3):331-8. PubMed ID: 16675781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance.
    Reves R; Heilig CM; Tapy JM; Bozeman L; Kyle RP; Hamilton CD; Bock N; Narita M; Wing D; Hershfield E; Goldberg SV;
    Int J Tuberc Lung Dis; 2014 May; 18(5):571-80. PubMed ID: 24903795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges.
    Magombedze G; Pasipanodya JG; Srivastava S; Deshpande D; Visser ME; Chigutsa E; McIlleron H; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S349-S358. PubMed ID: 30496464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study.
    Zierski M; Bek E
    Tubercle; 1980 Mar; 61(1):41-9. PubMed ID: 6989067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.